TY - JOUR
T1 - Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
AU - Blauvelt, Andrew
AU - Green, Lawrence J.
AU - Lebwohl, Mark G.
AU - Yamauchi, Paul S.
AU - Lin, Tina
AU - Martin, Gina
AU - Pillai, Radhakrishnan
PY - 2019/3
Y1 - 2019/3
N2 - Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published.1,2 HP/TAZ lotion was significantly more effective than individual active ingredients or vehicle, based on improvements in Investigator’s Global Assessment (IGA), body surface area (BSA) involvement, and signs and symptoms of psoriasis (erythema, plaque elevation, and scaling) at the target lesion as well as a synergistic benefit over individual active ingredients, and good tolerability.
AB - Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published.1,2 HP/TAZ lotion was significantly more effective than individual active ingredients or vehicle, based on improvements in Investigator’s Global Assessment (IGA), body surface area (BSA) involvement, and signs and symptoms of psoriasis (erythema, plaque elevation, and scaling) at the target lesion as well as a synergistic benefit over individual active ingredients, and good tolerability.
UR - http://www.scopus.com/inward/record.url?scp=85063779211&partnerID=8YFLogxK
M3 - Article
C2 - 30909352
AN - SCOPUS:85063779211
SN - 1545-9616
VL - 18
SP - 297
EP - 299
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 3
ER -